“It’s probably best to forget Valeant and instead invest in some other drug stocks,” argues today’s article. For investors looking for drug stocks but who want to avoid the possible negative side effects associated with crisis-plagued Valeant Pharmaceuticals, today’s article highlights four drug stocks that have favorable Zacks Ranks, as well as pipelines with potential breakout treatments for an array of diseases and disorders. For an overview of each company, including their current and up-and-coming drug candidates, CLICK HERE.